News | Heart Valve Technology | October 10, 2016

University Hospital Zurich Heart Team First to Perform Tricuspid Valve Repair with Cardioband

Device has traditionally been used for mitral valve repairs

Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano

October 10, 2016 — Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and cardiologists in for the first time repairing a leaky tricuspid valve using a new catheter technology.

Maisano, who is also director of the Clinic for Cardiovascular Surgery at USZ, co-director of the University Heart Center and professor at the University of Zurich, began using the Cardioband in Switzerland for repair of the mitral valve. Now he and his team have succeeded in an application at a leaky tricuspid a 75-year-old patient. The patient is doing well. 

The device has been used previously as a patient-friendly method of repairing a leaking mitral valve in the left heart. It is the minimally invasive alternative to open-heart surgery. Maisano was instrumental in the development of Cardioband, which can be gathered with the help of the leaky valve ring and contracted. For this, the band is placed using a catheter around the valve ring (annulus), and is fixed there by small screws and contracted with a wire, so that the flap closes again tightly.

The tricuspid valve separates the right atrium from the right chamber of the heart. A tricuspid regurgitation, i.e. an insufficient performance of the door, can cause serious symptoms. The backflow of blood into the ventricle and in the veins occur and can cause elevated pressure. This can result in problems in the legs and in the abdomen and liver damage. Also, atrial fibrillation may be associated with the consequences of tricuspid regurgitation. The current treatment of insufficiency of the tricuspid valve consisted of a surgical open-heart surgery using a heart-lung machine. 

Maisano explained the advantages of the new Cardioband method: "Since the insufficiency of this heart valve is often created as the result of mitral valve disease, open-heart surgery is often risky surgery. The use of the Cardioband minimally invasive therapy without the use of cardiopulmonary bypass protects the patient and reduces the risk.”

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init